EHA 2021: Journaal CLL

Bekijk hier het MEDtalks EHA-journaal over chronische lymfatische leukemie. In dit journaal bespreekt dr. Mark-David Levin zijn persoonlijke nieuwsselectie van EHA 2021. 

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:

1. FIRST INTERIM ANALYSIS OF ALPINE STUDY: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
2. FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
3. FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY
4. VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4-YEAR FOLLOW-UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
5. MRD-GUIDED OR FIXED 12 CYCLES OF VENETOCLAX CONSOLIDATION AFTER VENETOCLAX PLUS OBINUTUZUMAB TREATMENT IN FIRST-LINE FCR UNFIT PATIENTS WITH CLL: PRIMARY ENDPOINT ANALYSIS OF THE HOVON 139/GIVE TRIAL
6. CLINICAL IMPACT OF RECURRENT GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY
7. SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS

Bekijk hier het volledige interview met Lina van der Straten. 

Bekijk hier het volledige overzicht van onze EHA 2021 coverage.